Skip to content

Journal · Ophthalmology · Updated 15 November 2026

Eye

Read Eye research on DeepDyve. No university library needed.

Eye, published by Springer Nature under its current title since 1987, covers clinical and laboratory research in ophthalmology. Its papers range from glaucoma surgery and retinal gene therapy to eye infections and the eye complications of other diseases. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Eye
November 2026 issue

Eye at a glance

Full title
Eye
Abbreviation (NLM)
Eye (Lond)
Publisher
Springer Nature
Print ISSN
0950-222X
Online ISSN (eISSN)
1476-5454
Current title since
1987
Subjects
Ophthalmology
Access model
Hybrid: subscription, with an open access option
On DeepDyve
Research articles; availability varies by article

Ways to access Eye

27% of the articles Eye published from January 1 to November 14, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 27% of Eye articles published from January 1 to November 14, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
  3. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  4. A library. Your university, hospital or public library may subscribe to Eye. Check its journal list and whether it offers remote access.
  5. DeepDyve. Read Eye articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Recent Eye research worth reading

Published March to July 2026. Summaries describe what the authors report.

  1. LitStreamOphthalmology · Toxic epidermal necrolysis

    Ocular involvement in toxic epidermal necrolysis syndrome at Chelsea and Westminster Hospital: a 10-year retrospective analysis and review of current literature

    Reviewing 24 patients with toxic epidermal necrolysis treated in one burns unit between 2013 and 2023, the authors found ocular involvement in 16, with lamotrigine the most common culprit drug; nine had severe disease and amniotic membrane transplantation, and five developed sight-threatening complications.

    Pandey et al. · Eye, published online May 27, 2026 · DOI 10.1038/s41433-026-04566-2

  2. LitStreamOphthalmology · Air pollution

    Association between air pollutant exposure and ocular surface, anterior and middle segment and fundus eye diseases: epidemiological and mechanism evidence

    In a meta-analysis of 55 studies, the authors found air pollutant exposure was associated with eye disease overall (OR 1.26), including ocular surface diseases (OR 1.29), anterior and middle segment diseases (OR 1.22) and fundus diseases (OR 1.35).

    Li et al. · Eye, published online March 18, 2026 · DOI 10.1038/s41433-026-04404-5

  3. LitStreamOphthalmology · Retinal gene therapy

    Structural, functional and patient-reported 24-month outcomes of voretigene neparvovec in Portuguese patients with RPE65-associated disease

    Following 24 eyes of 12 Portuguese patients for two years after voretigene neparvovec gene therapy, the authors report improved light sensitivity on full-field stimulus testing, a median loss of 6 ETDRS letters of visual acuity, stable visual field function and adverse events in 91.7% of eyes.

    Machado et al. · Eye, published online April 17, 2026 · DOI 10.1038/s41433-026-04467-4

  4. LitStreamOphthalmology · Glaucoma surgery

    Multicentre study comparing ab-interno canaloplasty and trabecular micro-bypass stent in primary open-angle glaucoma

    Comparing 224 eyes treated with iTrack canaloplasty and 115 with iStent implantation for primary open-angle glaucoma, the authors found no significant difference in reduction of eye pressure or medications and 61% success in both groups, with more canaloplasty eyes medication-free (42% versus 29%).

    Kerr et al. · Eye, published online April 28, 2026 · DOI 10.1038/s41433-026-04483-4

  5. LitStreamOphthalmology · Ocular toxoplasmosis

    Azithromycin versus azithromycin-pyrimethamine and sulfadiazine-pyrimethamine for the treatment of ocular toxoplasmosis: a retrospective comparative case-series

    In a retrospective series of 493 people treated for toxoplasma-related retinochoroiditis, the authors found no significant difference in visual loss, recurrence or disease inactivation between azithromycin alone and two pyrimethamine combinations, with fewer adverse events on azithromycin (5% versus 28% and 20%).

    Bohn et al. · Eye, published online July 17, 2026 · DOI 10.1038/s41433-026-04685-w

See every Eye article on DeepDyve

Questions about Eye

How can I read Eye articles without a subscription?

27% of Eye articles published from January 1 to November 14, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read Eye articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Eye?

Eye’s NLM (PubMed) abbreviation is Eye (Lond).

What is the ISSN of Eye?

The print ISSN is 0950-222X and the online ISSN is 1476-5454.

Is Eye open access?

Eye is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 14, 2026, 207 of 764 Eye articles (27%) carry a Creative Commons license, per Crossref.

Eye articles on DeepDyve are licensed from Springer Nature. Journal facts as of 15 November 2026.

Start reading Eye today

One month free, then less than $2 a day. Eye, plus millions of articles from thousands of journals.

Start free month

Like this: